The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series J | Alive

Total Raised


Last Raised

$27M | 1 yr ago

About EndoGastric Solutions

EndoGastric Solutions is developing an endoscopic medical device and procedure that can restore the competency of the anti-reflux barrier, which is distorted in GERD patients and contributes to acid reflux and regurgitation. Designed specifically for performing incisionless reconstructive gastrointestinal procedures, the device is introduced into the body through the mouth, rather than through an abdominal incision.

EndoGastric Solutions Headquarter Location

18109 NE 76th Street Suite 100

Redmond, Washington, 98052,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing EndoGastric Solutions

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned EndoGastric Solutions in 1 CB Insights research brief, most recently on Mar 12, 2020.

Expert Collections containing EndoGastric Solutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EndoGastric Solutions is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,170 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

EndoGastric Solutions Patents

EndoGastric Solutions has filed 57 patents.

The 3 most popular patent topics include:

  • Digestive system
  • Esophagus disorders
  • Inflammations
patents chart

Application Date

Grant Date


Related Topics




Digestive system surgery, Esophagus disorders, Digestive system, Endoscopy, Inflammations


Application Date


Grant Date



Related Topics

Digestive system surgery, Esophagus disorders, Digestive system, Endoscopy, Inflammations



Latest EndoGastric Solutions News

Gastroesophageal Reflux Disease Devices Market Research Report - Global Forecast to 2026 - Cumulative Impact of COVID-19

Oct 18, 2021

Report - Global Forecast to 2026 - Cumulative Impact of COVID-19" - The Global Gastroesophageal Reflux Disease Devices Market size was estimated at USD 4,022.73 million in 2020 and expected to reach USD 4,550.91 million in 2021, at a CAGR 13.46% to reach USD 8,585.61 million by 2026. Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period. Market Segmentation & Coverage: This research report categorizes the Gastroesophageal Reflux Disease Devices to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Product Type, the market was studied across Diagnostic Devices, Esophagoscopes and Gastroscopes, Fundoplication Devices, Manometry System, PH Monitoring System, Radiofrequency Ablation Devices, Sphincter Augmentation Devices, Treatment Devices, and Ultrasonic Surgical Endostapler. Based on Procedure Type, the market was studied across Diagnostic Procedures, Fundoplication Procedures, Magnetic Sphincter Augmentation, and Radiofrequency Thermal Ablation. Based on Device Type, the market was studied across Bravo Reflux Testing System, Digitrapper reflux testing system, LINX Management System, MUSE –Medigus Ultrasonic Surgical Endostapler, Others, and Stretta Therapy. Based on Surgery Type, the market was studied across Invasive and Non-invasive. The Invasive is further studied across Linx Reflux Management and Medigus Ultrasonic Surgical Endostapler. The Non-invasive is further studied across Endocinch Endolumminal gastroplication, Endoscopic Plicator System, EsophyX, Plexiglas poly-methyl-methacrylate (PMMA) microspheres, and Stretta. Based on Route of Administration, the market was studied across Oral and Parenteral. Based on Dosage Form, the market was studied across Liquid and Solid. Based on End-User, the market was studied across Government, Hospitals, Medical Practitioners, and Others. Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Gastroesophageal Reflux Disease Devices Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. Competitive Scenario: The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service. Company Usability Profiles: The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Gastroesophageal Reflux Disease Devices Market, including Addex Pharmaceuticals Ltd., Aros Pharma ApS, AstraZeneca Plc, C. R. Bard, Inc.,, Eisai Co., Ltd, EndoGastric Solutions, Inc., KARL STORZ SE & Co. KG, MediGus Ltd., Olympus Corporation, PENTAX Medical (Global), Pfizer Inc., Takeda Pharmaceutical Company Limited, and The Procter & Gamble Company. The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: 1. What is the market size and forecast of the Global Gastroesophageal Reflux Disease Devices Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gastroesophageal Reflux Disease Devices Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastroesophageal Reflux Disease Devices Market? 4. What is the competitive strategic window for opportunities in the Global Gastroesophageal Reflux Disease Devices Market? 5. What are the technology trends and regulatory frameworks in the Global Gastroesophageal Reflux Disease Devices Market? 6. What is the market share of the leading vendors in the Global Gastroesophageal Reflux Disease Devices Market? 7. What modes and strategic moves are considered suitable for entering the Global Gastroesophageal Reflux Disease Devices Market?

EndoGastric Solutions Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EndoGastric Solutions Rank

  • When was EndoGastric Solutions founded?

    EndoGastric Solutions was founded in 2002.

  • Where is EndoGastric Solutions's headquarters?

    EndoGastric Solutions's headquarters is located at 18109 NE 76th Street, Redmond.

  • What is EndoGastric Solutions's latest funding round?

    EndoGastric Solutions's latest funding round is Series J.

  • How much did EndoGastric Solutions raise?

    EndoGastric Solutions raised a total of $303.94M.

  • Who are EndoGastric Solutions's competitors?

    Competitors of EndoGastric Solutions include Ivenix, ValenTx, Uptake Medical, Torax Medical, AxoGen and 11 more.

You May Also Like


Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.


VytronUS is developing an integrated imaging and ablation platform for cardiac electrophysiologists. Harnessing the capability of ultrasound energy, the company's system creates a high resolution image of the interior of the heart for procedure planning and allows the physician to draw a desired treatment pattern on the image at the workstation.

Axial Biotech

Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial ( is located in Salt Lake City, Utah.

NeoGraft Technologies

NeoGraft Technologies is developing Angioshield, an intraperative system that creates a micro-fibrous, polymer sleeve intimately surrounding the outside surface of a harvested vein to mechanically reinforce and protect it from overdilation.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.


MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.